Author Archives: Millie Nelson

Samsung Biologics eyes up ADC market for 2023

Samsung Biologics says it is looking at moving into the ADC market and has space free at its plant number four to add capability. It comes as no surprise that biopharma companies around the world keep an eye on trends and modalities that look to be promising, and Korean contract development manufacturing organization (CDMO) Samsung Biologics is no different. James Park, executive vice president of global sales at Samsung Biologics, spoke to BioProcess Insider at CPHI, Frankfurt and pointed to antibody…

Touchlight receives $2.4m to advance doggybone DNA platform

The Bill & Melinda Gates Foundation has awarded Touchlight $2.4 million in funding to further preclinical development of its doggybone DNA vaccine platform. According to Touchlight, the funding will be used to advance preclinical data that has shown the potential of nanoparticle-formulated doggybone DNA (dbDNA) to provide strong antibody titers and durable T cell responses following vaccine administration. Part of the grant will also be put towards investigating the performance of dbDNA for therapeutic monoclonal antibody (mAb) manufacturing. If the…

UK Uni to train frontline healthcare staff in CGT production

The center for Advanced Therapies Manufacturing Training at the University of Birmingham has introduced training courses aimed at bolstering the industry’s capabilities for advanced cell and gene therapy production.   The course programs are specifically aimed at frontline healthcare practitioners and consist of virtual reality (VR) training components to upskill staff to produce and administer advanced therapy medicinal products (ATMP’s) to patients. “The aim of the courses is to provide an introduction to CGTs and ATMPs with an emphasis on…

Sartorius and Exopharm to develop large-scale exosome tech

Sartorius BIA Separations (BIA) and Exopharm have signed a joint research agreement to address the technical challenges of large-scale exosomes for non-viral drug delivery. BIA – a chromatography firm acquired by Sartorius in October 2020 for $423 million – will use its Convective Interaction Media (CIM) monolith chromatography alongside Exopharm’s patented LEAP technology to advance large-scale therapeutic exosome production and commercialization. BIA claims its CIM monolith chromatography columns allow high-throughput, resolution separation, and capacity. Furthermore, the firm says it has…

Healiva to speed regenerative skin therapy launch with B.Braun asset buy

The acquisition of B. Braun Medical AG Switzerland’s manufacturing assets will advance the launch of personalized skin regeneration therapy, EpiDex, says Healiva. Healiva, a firm that delivers medicine for individuals with chronic and acute wounds, has acquired pharmaceutical device company, B.Braun’s, manufacturing assets for an undisclosed fee. The acquisition includes a qualified cell bank, which Healiva says is vital for the GMP-compliant production of its first cell therapy product, EpiDex. According to Healiva, the acquisition of a qualified fibroblast cell…

RVAC and A*STAR partner to build mRNA capabilities in Singapore

RVAC Medicines and the Agency for Science, Technology and Research (A*STAR) will develop solutions to construct mRNA manufacturing and analytics capabilities in Singapore. RVAC, a messenger RNA (mRNA) technology platform firm headquartered in Singapore, will work with research and development (R&D) agency A*STAR to jointly establish a laboratory. The joint laboratory will be located at A*STAR’S Bioprocessing Technology Institute (BTI) in Singapore and will be used to advance a preclinical production platform, which will enable the generation of raw materials…

CGT Catapult looks to Edinburgh to create an iPSC cluster

CGT Catapult says its venture into Edinburgh, Scotland and northern England will focus on the development and production of induced pluripotent stem cells (iPSCs). The Cell and Gene Therapy Catapult (CGT Catapult) announced in June 2021 that it would construct offices and laboratories in Edinburgh, Scotland to support the cell and gene therapy sector and drive product development but did not disclose a specific modality. Now, the organization has confirmed to BioProcess Insider that its move to create a cluster…

KBI expansion strategy in question following CEO’s swift exit

Just six months after accepting the role, Mark Womack is no longer serving as the CEO of KBI Biopharma and Selexis. The firm released a statement detailing that Tim Lowery, president of JSR Life Sciences, has been appointed as interim CEO as the company searches to identify someone for a permanent position. The reasons behind his departure have not been disclosed despite BioProcess Insider reaching out to Womack directly for additional information. However, a spokesperson for KBI told us that…

Thermo Fisher launches AAV tech to reduce costs by 50%

Thermo Fisher Scientific has introduced the Gibco CTS adeno-associated virus (AAV)- MAX Helper Free production system, which it says can save time and reduce costs by 50%. According to the firm, the all-in-one solution production system is “the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.” Additionally, Thermo says that the system has been designed to meet both clinical and commercial demands of AAV-based gene therapies, as well as bringing products to market…

eBook: Vaccines — From Disease Prevention to Treatment

For over two years, the biopharmaceutical industry has revolved around rapid development, manufacture, and rollout of vaccines in response to the COVID-19 pandemic. Now as the world reverts to some sense of normality, demand has plummeted for the likes of J&J’s viral vector vaccine and Moderna’s messenger RNA (mRNA) vaccine, resulting in the lowering of financial forecasts, ending of manufacturing contracts, and freeing of production capacity. But where do vaccines — the great pharmaceutical success story of the past few…